Literature DB >> 17606686

In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.

Charles J Gill1, George K Abruzzo, Amy M Flattery, Andrew S Misura, Ken Bartizal, Emily J Hickey.   

Abstract

A novel oxazolidinone, AM 7359, was evaluated in two mouse models of Staphylococcus aureus infection. AM 7359 and linezolid were equally efficacious in a methicillin-susceptible S. aureus organ burden model and a methicillin-resistant S. aureus localized infection model. However, AM 7359 was eightfold more efficacious than linezolid against a linezolid- and methicillin-resistant S. aureus strain in this localized (thigh) infection model.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17606686      PMCID： PMC2043186          DOI： 10.1128/AAC.01567-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Linezolid and reversible myelosuppression.

Authors:  S L Green; J C Maddox; E D Huttenbach
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

2.  Linezolid resistance in clinical isolates of Staphylococcus aureus.

Authors:  Peter Wilson; J A Andrews; R Charlesworth; R Walesby; M Singer; D J Farrell; M Robbins
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

3.  Antimicrobial resistance issues of the future.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1996-08       Impact factor: 2.803

4.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

5.  The use of the angular transformation in biological assays.

Authors:  L F KNUDSEN; J M CURTIS
Journal:  J Am Stat Assoc       Date:  1947-06       Impact factor: 5.033

6.  Thrombocytopenia associated with linezolid therapy.

Authors:  Kinan Attassi; Ellie Hershberger; Rabiul Alam; Marcus J Zervos
Journal:  Clin Infect Dis       Date:  2002-01-17       Impact factor: 9.079

7.  In vivo pharmacodynamics of a new oxazolidinone (linezolid).

Authors:  D Andes; M L van Ogtrop; J Peng; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 8.  Linezolid--a review of the first oxazolidinone.

Authors:  R Norrby
Journal:  Expert Opin Pharmacother       Date:  2001-02       Impact factor: 3.889

9.  Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient.

Authors:  Imad Dibo; Satish K Pillai; Howard S Gold; Maria R Baer; Meir Wetzler; James L Slack; Peggy A Hazamy; Donna Ball; Chiu Bin Hsiao; Philip L McCarthy; Brahm H Segal
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 10.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431
View more
  7 in total

1.  Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents.

Authors:  Hao Wang; Charles J Gill; Sang H Lee; Paul Mann; Paul Zuck; Timothy C Meredith; Nicholas Murgolo; Xinwei She; Susan Kales; Lianzhu Liang; Jenny Liu; Jin Wu; John Santa Maria; Jing Su; Jianping Pan; Judy Hailey; Debra Mcguinness; Christopher M Tan; Amy Flattery; Suzanne Walker; Todd Black; Terry Roemer
Journal:  Chem Biol       Date:  2013-02-21

2.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

3.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

4.  In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Authors:  Jamese J Hilliard; Jeffrey Fernandez; John Melton; Mark J Macielag; Raul Goldschmidt; Karen Bush; Darren Abbanat
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

5.  Linezolid Exerts Greater Bacterial Clearance but No Modification of Host Lung Gene Expression Profiling: A Mouse MRSA Pneumonia Model.

Authors:  Jiwang Chen; Gang Feng; Yang Song; Juliane B Wardenburg; Simon Lin; Ichiro Inoshima; Michael Otto; Richard G Wunderink
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

6.  Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model.

Authors:  Batu K Sharma-Kuinkel; Yurong Zhang; Qin Yan; Sun Hee Ahn; Vance G Fowler
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

7.  Chemical Genetic Analysis and Functional Characterization of Staphylococcal Wall Teichoic Acid 2-Epimerases Reveals Unconventional Antibiotic Drug Targets.

Authors:  Paul A Mann; Anna Müller; Kerstin A Wolff; Thierry Fischmann; Hao Wang; Patricia Reed; Yan Hou; Wenjin Li; Christa E Müller; Jianying Xiao; Nicholas Murgolo; Xinwei Sher; Todd Mayhood; Payal R Sheth; Asra Mirza; Marc Labroli; Li Xiao; Mark McCoy; Charles J Gill; Mariana G Pinho; Tanja Schneider; Terry Roemer
Journal:  PLoS Pathog       Date:  2016-05-04       Impact factor: 6.823
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.